Explorer
Pfizer Inc seeks permission for emergency use of vaccine
The Phase 3 study of our COVID19 vaccine candidate has met all primary efficacy endpoints. The study reached 170 confirmed cases of COVID19, with the vaccine candidate BNT162b2 demonstrating 95% efficacy beginning 28 days after the first dose: Pfizer Inc.
The company now has 170 infections on which its data are based. Only eight infections were recorded among volunteers who got the vaccine, while only one got severe disease.
The company now has 170 infections on which its data are based. Only eight infections were recorded among volunteers who got the vaccine, while only one got severe disease.
India
BREAKING NEWS: Champat Rai and Anil Mishra Get Clean Chit in Ram Temple Donation Case
POLITICAL ROW: Vande Mataram Controversy Intensifies After Congress Sings Only Two Verses
BIG CONTROVERSY: Naxalism Victims Question Leaders Calling Themselves ‘Ideological Naxals’
Breaking News: Delhi Police Tells Supreme Court No Excessive Force Used During July 20 Student Protest
Breaking: Ram Temple Donation Theft SIT Report Gives Clean Chit to Champat Rai, Anil Mishra
View More
Top Headlines
India
‘Take Gyanesh Kumar To US’: Pawan Khera Takes Dig After Trump Praises Indian Polls
World
Trump Shares Map Calling Strait Of Hormuz ‘New US Territory’; Iran Hits Back
Business
Tata Sons AGM Postponed For First Time In 100 Years Over Quorum Crisis: Here's Why
News
CJP Warns Centre Of Action Over Delay In Withdrawing FIRs Against Protesters
Trending News
